These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 9525737

  • 1. Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL.
    Amarante-Mendes GP, McGahon AJ, Nishioka WK, Afar DE, Witte ON, Green DR.
    Oncogene; 1998 Mar; 16(11):1383-90. PubMed ID: 9525737
    [Abstract] [Full Text] [Related]

  • 2. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X, Jin Y, Cheng C, Zhang H, Zou W, Zheng Q, Lu Z, Chen Q, Lai Y, Pan J.
    Clin Cancer Res; 2009 Mar 01; 15(5):1686-97. PubMed ID: 19240172
    [Abstract] [Full Text] [Related]

  • 3. Cooperative and redundant effects of STAT5 and Ras signaling in BCR/ABL transformed hematopoietic cells.
    Hoover RR, Gerlach MJ, Koh EY, Daley GQ.
    Oncogene; 2001 Sep 13; 20(41):5826-35. PubMed ID: 11593388
    [Abstract] [Full Text] [Related]

  • 4. STI-571 (imatinib mesylate) enhances the apoptotic efficacy of pyrrolo-1,5-benzoxazepine-6, a novel microtubule-targeting agent, in both STI-571-sensitive and -resistant Bcr-Abl-positive human chronic myeloid leukemia cells.
    Greene LM, Kelly L, Onnis V, Campiani G, Lawler M, Williams DC, Zisterer DM.
    J Pharmacol Exp Ther; 2007 Apr 13; 321(1):288-97. PubMed ID: 17202400
    [Abstract] [Full Text] [Related]

  • 5. The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in human chronic myeloid leukaemia cells.
    Bright SA, Greene LM, Greene TF, Campiani G, Butini S, Brindisi M, Lawler M, Meegan MJ, Williams DC, Zisterer DM.
    Biochem Pharmacol; 2009 Feb 01; 77(3):310-21. PubMed ID: 19014913
    [Abstract] [Full Text] [Related]

  • 6. Induction of apoptosis by apicidin, a histone deacetylase inhibitor, via the activation of mitochondria-dependent caspase cascades in human Bcr-Abl-positive leukemia cells.
    Cheong JW, Chong SY, Kim JY, Eom JI, Jeung HK, Maeng HY, Lee ST, Min YH.
    Clin Cancer Res; 2003 Oct 15; 9(13):5018-27. PubMed ID: 14581377
    [Abstract] [Full Text] [Related]

  • 7. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
    Rahmani M, Nguyen TK, Dent P, Grant S.
    Mol Pharmacol; 2007 Sep 15; 72(3):788-95. PubMed ID: 17595328
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. N-Benzyladriamycin-14-valerate (AD 198) cytotoxicty circumvents Bcr-Abl anti-apoptotic signaling in human leukemia cells and also potentiates imatinib cytotoxicity.
    Lothstein L, Savranskaya L, Sweatman TW.
    Leuk Res; 2007 Aug 15; 31(8):1085-95. PubMed ID: 17187856
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. "Loop" domain is necessary for taxol-induced mobility shift and phosphorylation of Bcl-2 as well as for inhibiting taxol-induced cytosolic accumulation of cytochrome c and apoptosis.
    Fang G, Chang BS, Kim CN, Perkins C, Thompson CB, Bhalla KN.
    Cancer Res; 1998 Aug 01; 58(15):3202-8. PubMed ID: 9699642
    [Abstract] [Full Text] [Related]

  • 14. Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein.
    Scappini B, Gatto S, Onida F, Ricci C, Divoky V, Wierda WG, Andreeff M, Dong L, Hayes K, Verstovsek S, Kantarjian HM, Beran M.
    Cancer; 2004 Apr 01; 100(7):1459-71. PubMed ID: 15042680
    [Abstract] [Full Text] [Related]

  • 15. ts BCR-ABL kinase activation confers increased resistance to genotoxic damage via cell cycle block.
    Nishii K, Kabarowski JH, Gibbons DL, Griffiths SD, Titley I, Wiedemann LM, Greaves MF.
    Oncogene; 1996 Nov 21; 13(10):2225-34. PubMed ID: 8950990
    [Abstract] [Full Text] [Related]

  • 16. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
    Nguyen TK, Rahmani M, Gao N, Kramer L, Corbin AS, Druker BJ, Dent P, Grant S.
    Clin Cancer Res; 2006 Apr 01; 12(7 Pt 1):2239-47. PubMed ID: 16609040
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. BAX/BCL-XL gene expression ratio inversely correlates with disease progression in chronic myeloid leukemia.
    Gonzalez MS, De Brasi CD, Bianchini M, Gargallo P, Moiraghi B, Bengió R, Larripa IB.
    Blood Cells Mol Dis; 2010 Oct 15; 45(3):192-6. PubMed ID: 20728382
    [Abstract] [Full Text] [Related]

  • 19. Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis.
    Wang Z, Sampath J, Fukuda S, Pelus LM.
    Cancer Res; 2005 Sep 15; 65(18):8224-32. PubMed ID: 16166298
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.